

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## SIDE EFFECTS OF COVID-19 VACCINES: A SYSTEMATIC REVIEW/META-ANALYSIS PROTOCOL OF RANDOMIZED TRIALS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050278
Article Type:	Protocol
Date Submitted by the Author:	17-Feb-2021
Complete List of Authors:	Medeiros, Kleyton ; Universidade Federal do Rio Grande do Norte Costa, Ana Paula; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Sarmiento, Ayane Cristine ; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Freitas, Cijara Leonice; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Gonçalves, Ana; Universidade Federal do Rio Grande do Norte,
Keywords:	COVID-19, IMMUNOLOGY, Adverse events < THERAPEUTICS, Clinical trials < THERAPEUTICS, TOXICOLOGY

SCHOLARONE™  
Manuscripts

1  
2 **SIDE EFFECTS OF COVID-19 VACCINES: A SYSTEMATIC REVIEW/META-ANALYSIS**  
3  
4 **PROTOCOL OF RANDOMIZED TRIALS**  
5  
6  
7

8  
9 Kleyton Santos Medeiros<sup>1#</sup>, Ana Paula Ferreira Costa<sup>1#</sup>, Ayane Cristine Sarmento<sup>1#</sup>, Cijara  
10 Leonice Freitas, Ana Katherine Gonçalves<sup>1,2\*</sup>  
11  
12

13  
14 <sup>1</sup> Health Sciences Postgraduate Program, Federal University of Rio Grande do Norte  
15 (UFRN), Natal, RN, Brazil. Email: kleyton\_medeiros@hotmail.com / ana-paula-  
16 rf@hotmail.com / ayane\_cris@hotmail.com / cijara\_enfer@hotmail.com  
17  
18

19 <sup>2</sup> Department of obstetrics and gynaecology, Federal University of Rio Grande do Norte  
20 (UFRN), Natal, RN, Brazil. Email: anakatherine\_ufrnet@yahoo.com.br  
21  
22

23  
24 # KSM, ACS, APFC are considered first authors.  
25  
26

27 \*Correspondence

28 Ana Katherine Gonçalves, Major Laurentino de Morais St 1218/1301, Natal, RN, Brazil.

29 Email: anakatherine\_ufrnet@yahoo.com.br

30  
31 ORCID ID: <https://orcid.org/0000-0002-8351-5119>  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** This systematic review and meta-analysis protocol aims to compare the side effects, safety, and toxicity of coronavirus disease 2019 (COVID-19) vaccines available globally, including their combinations.

**Materials and Methods:** We will select randomized controlled trial (RCT)-type studies that evaluated the side effects of the COVID-19 vaccine. PubMed, Web of Science, Embase, CINAHAL, PsycINFO, LILACS, SCOPUS, and the Cochrane Library will be searched for eligible studies. Three reviewers will independently screen and select studies, assess methodological quality, and extract data. A meta-analysis will be performed, if possible, and the Grading of Recommendations Assessment Development and Evaluation (GRADE) Summary of Findings will be presented.

**Ethics and Dissemination:** This study will review published data, and thus it is unnecessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal.

**Systematic review registration:** CRD42021231101.

**Keywords:** COVID-19; SARS-Cov-2; COVID-19 vaccine; SARS-CoV-2 vaccine

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The results obtained in this systematic review will, through evidence-based medicine, indicate the rates of adverse reactions (local and systemic) of COVID-19 vaccines.
- Four authors, KSM, APFC, ACS, and CLF will select the articles independently, using titles and abstracts.
- To the best of our knowledge, there are no existing reviews regarding the side effects of COVID-19 vaccines.
- Potential limitations include a great diversity of existing vaccines, still being tested, and heterogeneity of systemic and local adverse events.

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a large number of global coronavirus disease (COVID-19) cases. It is a highly transmissible virus among humans that has become a significant public health issue [1]. Symptoms include fever, dry cough, fatigue, shortness of breath, chills, muscle pain, headache, gastric disorders, and weight loss, often leading to death [2].

Strategies such as social isolation, personal hygiene, and frequent hand washing have been implemented; however, a protective vaccine is required to achieve sufficient herd immunity to SARS-CoV-2 infection to ultimately control the COVID-19 pandemic [3]. To meet the urgent need for a vaccine, a reduction in the development schedule has been proposed, from 10–15 years to 1–2 years [4].

COVID-19 vaccine formulations have different compositions, from attenuated virus vaccines to inactive virus vaccines [5]. Attenuated vaccines introduce a mild infection that resembles the actual infection, leading to a robust immune response that can last for years. This type of vaccine's main disadvantage is its potential safety problem since people with compromised immune systems can revert to a virulent strain [6]. Inactivated vaccines are relatively safer, as live pathogens are not involved, but they may be less immunogenic and often require multiple doses to establish immune memory [5].

Developing any vaccine needs to ensure that safety risks are identified and quantified against potential benefits. Among the potential risks raised in the context of COVID-19, vaccine development is the security and affectivity of immune responses elicited by a vaccine. Here, this systematic review protocol aims to assess the side effects, safety, and toxicity of vaccines against COVID-19.

## OBJECTIVES

This systematic review and meta-analysis protocol aims to compare the side effects, safety, and toxicity of COVID-19 vaccines available globally, including their combination.

### Review question

What are the rates of adverse reactions (local and systemic) to COVID-19 vaccines?

## MATERIALS AND METHODS

The meta-analysis protocol follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines [7,8]. This protocol is

1  
2 registered with the International Prospective Register of Systematic Reviews  
3 (CRD42021231101).  
4  
5

### 6 7 **Eligibility criteria**

8  
9 The inclusion criteria involved [1] randomized controlled trial (RCT)-type studies that  
10 evaluated the side effects of the COVID-19 vaccine; [2] experiments involving human  
11 beings; [3] studies evaluating the safety, immunogenicity, and efficacy parameters of the  
12 vaccines; [4] studies that presented similar vaccination protocols; [5] studies published since  
13 January 2020; and [6] studies published in any language.  
14  
15

16  
17 The exclusion criteria were as follows: [1] observational studies, and [2] case reports,  
18 meeting abstracts, review papers, and commentaries.  
19  
20  
21

### 22 23 **Patients, intervention, comparison, outcome strategy, and types of studies**

- 24 • Patients: Healthy adults aged 18 years or older who were HIV-negative and previously  
25 SARS-CoV-2 infection-free
- 26 • Intervention: COVID-19 vaccine or a combination of vaccines against COVID-19.
- 27 • Comparator/control: Placebo
- 28 • Outcome: safety, tolerability, and immunogenicity of the COVID-19 vaccine or the  
29 combination of vaccines against COVID-19
- 30 • Types of studies: randomized controlled trials (RCT)
- 31
- 32
- 33
- 34
- 35
- 36
- 37

### 38 39 **Information sources**

40 The following databases will be searched: Medline/PubMed, clinicaltrials.gov, Web  
41 of Science, Embase, CINAHAL, Latin American and Caribbean Health Sciences Literature,  
42 SCOPUS, and Cochrane Central Controlled Trials Registry. Furthermore, eligible studies  
43 may also be selected from the reference lists of retrieved articles.  
44  
45  
46  
47

### 48 49 **Search strategy**

50 Our keyword search will be based on Medical Subject Headings (MeSH) according  
51 to the following combination: (COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR coronavirus)  
52 AND (vaccines OR vaccination OR COVID-19 vaccine OR SARS-CoV-2 vaccine OR  
53 BNT162 vaccine OR mRNA-1273 vaccine OR Covid-19 aAPC vaccine OR INO-4800  
54 vaccine OR LV-SMENP-DC COVID-19 vaccine OR Ad5-nCoV vaccine OR ChAdOx1  
55 COVID-19 vaccine OR MNA SARS-CoV-2 S1 subunit vaccines OR PittCoVacc) AND  
56  
57  
58  
59  
60

(Toxicity OR Vaccine Immunogenicity OR side effects OR adverse events) AND  
(randomized controlled trial OR double blind method OR clinical trial) (Table 1).

**Table 1 Medline search strategy**

Search items	
1	COVID-19
2	SARS-CoV-2
3	2019-nCoV
4	Coronavirus
5	Or/1-4
6	vaccines
7	vaccination
8	COVID-19 vaccine
9	SARS-CoV-2 vaccine
10	BNT162 vaccine
11	mRNA-1273 vaccine
12	COVID-19 aAPC vaccine
13	INO-4800 vaccine
14	LV-SMENP-DC COVID-19 vaccine
15	Ad5-nCoV vaccine
16	ChAdOx1 COVID-19 vaccine
17	MNA SARS-CoV-2 S1 subunit vaccines
18	PittCoVacc
19	Or/6-18
20	Toxicity
21	Vaccine Immunogenicity

22	side effects
23	adverse events
24	Or/20-24
25	randomized controlled trial
26	double-blind method
27	clinical trial
28	Or/25-28
29	5 AND 19 AND 24 AND 28

### Study records

Four researchers (KSM, APFC, ACS, and CLF) performed the selection of the studies of interest. Titles and abstracts will be read independently, and duplicate studies will be excluded. The same authors analyzed the selected texts to assess compliance with the inclusion criteria. A fifth reviewer, AKG, solves the discrepancies. The flowchart of this study is shown in Figure 1.

### [Insert Figure 1]

**Figure 1** Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

### Data collection process and management

A standardized data extraction form was developed and tested. Data from each included study will be extracted independently by two reviewers (ACS and APFC), and any subsequent discrepancies will be resolved through discussion with a third reviewer (AKG). The data extracted will include information on authors, the year of publication, study location, type of study, main objectives, population, type of vaccine, follow-up of participants, rates of systemic events, gastrointestinal (GI) symptoms, injection site-related adverse effects, and serious vaccine-related adverse events (Table 2). Furthermore, participant characteristics (e.g., mean age, gender), and results for immunogenicity will be collected.



**Table 2** Adverse events of COVID-19 vaccines**ADVERSE EVENTS**

<b>SYSTEMIC EVENTS REACTIONS (9, 10)</b>	Fever or hyperthermia or feverish, headaches, fatigue, vomiting, diarrhea, muscle pain, joint pain, throat pain, cough, nausea, functional gastrointestinal disorder, dyspnea, appetite impaired, dizziness, mucosal abnormality, pruritus [9,10], oropharyngeal pain, hypersensitivity, syncope [10], asthenia, heartbeat, rhinorrhea, malaise, sore throat (throat irritation), pain in the oropharynx (pharyngalgia), hives, nasal congestion, sneezing, changes in laboratory variables [11], warmth [12].
<b>INJECTION SITE ADVERSE REACTIONS (9–11)</b>	Pain, induration, redness or erythema, swelling, itch, and muscular weakness [9–11].
<b>SERIOUS VACCINE-RELATED ADVERSE EVENT</b>	Deaths, hospitalisation [12].

The study authors will be contacted in case of missing data and/or to resolve any uncertainties. In addition, any additional information will be recorded. All data entries will be checked twice. If we find a set of articles with similar characteristics based on the information in the data extraction table, we will perform a meta-analysis using a random-effects model. If there are data that are not clear in some articles, the corresponding author will be contacted for possible clarification.

**Risk of bias in individual studies**

Three authors, KSM, ACAS, and APFC, will independently assess the risk of bias in the eligible studies using the Cochrane risk-of-bias tool [13]. The Risk of Bias 2 (RoB 2) tool [14] will be used to assess the risk of bias. Bias is assessed as a judgment (high, low, or unclear) for individual elements from five domains (selection, performance, attrition, reporting, and others).

**Data synthesis and analysis**

1  
2 Data will be entered into the Review Manager software (RevMan5.2.3). This software  
3 allows the user to enter protocols; complete reviews; include text, characteristics of the  
4 studies, comparison tables, and study data; and perform meta-analyses. For dichotomous  
5 outcomes, we extracted or calculated the OR and 95% CI for each study. In case of  
6 heterogeneity ( $I^2 \geq 50\%$ ), the random-effects model will be used to combine the studies to  
7 calculate the OR and 95% CI, using the DerSimonian–Laird algorithm in the meta for  
8 package, which provides functions for conducting meta-analyses in R.  
9  
10  
11  
12  
13  
14

## 15 **Meta-bias**

16  
17 To grade the strength of evidence from the included data, we will use the Grading of  
18 Recommendation Assessment, Development, and Evaluation (GRADE) [15] approach. The  
19 summary of the assessment will be incorporated into broader measurements to ensure the  
20 judgment of the risk of bias, consistency, directness, and precision. The quality of the  
21 evidence will be assessed based on the risk of bias, indirectness, inconsistency,  
22 imprecision, and publication bias.  
23  
24  
25  
26  
27  
28  
29  
30

## 31 **DISCUSSION**

32  
33 The COVID-19 pandemic represents one of the most significant global public health  
34 crises of this generation. Lockdown, quarantine, contact tracing, and case isolation are  
35 suggested as effective interventions to control the epidemic; however, they may present  
36 different results in different contexts because of the specific features of the COVID-19. The  
37 lack of implementation of continued interventions or effective treatments further contributes  
38 to discovering and using effective and safe vaccines [16,17].  
39  
40  
41  
42

43 For all these reasons, scientists worldwide entered a real race time to find a vaccine  
44 candidate useful in fighting the new coronavirus pandemic. Nevertheless, it is essential to  
45 note that a vaccine's production is not easy and quick. Before being released to the  
46 population, a vaccine must go through three phases of clinical trials that prove its safety and  
47 effectiveness. More volunteers are recruited at each stage, and the researchers analyze the  
48 test results to ensure that a vaccine can be licensed [19-22]. As of December 2020, more  
49 than 200 vaccine candidates for COVID-19 have been developed. Of these, at least 52  
50 vaccine candidates are being tested in humans [18]. In December 2020, some vaccine  
51 candidates against COVID-19 received authorization for emergency use in some countries.  
52 Comprehensive studies of several vaccine candidates have reported encouraging  
53 preliminary results. On December 31, 2020, the World Health Organization (WHO) listed the  
54  
55  
56  
57  
58  
59  
60

1 mRNA vaccine against COVID-19 for emergency use, making this Pfizer/BioNTech  
2 immunizer the first to receive WHO emergency validation from the beginning outbreak [18].  
3

4  
5 The development and approval of several safe and effective vaccines less than a  
6 year after the virus was isolated and sequenced is an outstanding scientific achievement.  
7 However, it is essential to note that the first vaccine approval does not mean that the work  
8 is done, on contrary. More vaccines are on the way that should be evaluated to ensure that  
9 enough doses are available to vaccinate everyone. Other prevention approaches are likely  
10 to emerge in the coming months, including monoclonal antibodies, hyper-immune globulin,  
11 and convalescent titer. If proven effective, these approaches could be used in high-risk  
12 individuals, including health care workers, other essential workers, and older adults [23]. It  
13 is also essential to maintain protective measures such as washing hands frequently with  
14 soap and water or gel alcohol and covering the mouth with a forearm when coughing or  
15 sneezing.  
16  
17

18  
19 In this context, in a previous search in the databases, we can see that there are few  
20 published studies on this topic, and the only systematic review [24] found is still in the pre-  
21 print format and presents limitations in current studies, such as the short follow-up time and  
22 small size of subjects. Furthermore, this pre-print [24] has some weaknesses, such as the  
23 lack of registration in Prospero; the small number of studies included a small number of  
24 patients involved, taking into account the beginning of the vaccine use and the speed at  
25 which the systematic review was written. Thus, it is expected that some questions will remain  
26 unclear.  
27  
28

29 For this reason, this review is necessary and essential. The latter is a well-defined  
30 protocol registered with Prospero, well planned to include the largest possible number of  
31 vaccines, a significant number of vaccinated patients, thus providing safe and reliable  
32 results regarding the use of vaccines.  
33  
34  
35  
36  
37

## 38 **CONCLUSION**

39 During the COVID-19 pandemic, humanity has experienced the most severe health  
40 crisis in recent years. So far, no vaccine has been considered safe and effective for use in  
41 the population. The study of the efficacy and safety of these vaccines is of utter importance  
42 to control this epidemic plaguing the entire world.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Contributors

KSM, ACS, and APFC contributed to the design of this review. KSM and ACS drafted the protocol manuscript, and APFC and AKG revised it. KSM, AKG, and APFC developed the search strategies, and KSM, CLF, and ACAS will implement them. KSM, CLF, ACS, and APFC will track potential studies, extract data, and assess quality. In cases of disagreement between the data extractors, AKG will advise on the methodology and will work as a referee. KSM will complete the data synthesis. All authors will approve the final version for publication.

## Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

## Competing interests

None declared.

## Patient and public involvement statement

Patients were not involved in the development of this protocol.

## REFERENCES

- [1] Jianli Liu, Yuan Zhou, Chuanyu Ye, Guangming Zhang, Feng Zhang and Chunjuan Song. The spatial transmission of SARS-CoV-2 in China under the prevention and control measures at the early outbreak. *Arch Public Health*. 2021; 79: 8. doi: 10.1186/s13690-021-00529-z.
- [2] Simran Preet Kaur, Vandana Gupta. COVID-19 Vaccine: A comprehensive status report. *Virus Res*. 2020;15;288:198114. doi: 10.1016/j.virusres.2020.198114.
- [3] Barney S Graham. Rapid COVID-19 vaccine development. *Science*. 2020;368(6494):945-946. doi: 10.1126/science.abb8923.
- [4] Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, Matthew S Miller, Brian D Lichty, Zhou Xing. Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol*. 2020;20(10):615-632. doi: 10.1038/s41577-020-00434-6.

- 1  
2 [5] Jieliang Wang, Ying Peng, Haiyue Xu, Zhengrong Cui, Robert O Williams 3rd. The  
3 COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. *AAPS*  
4 *PharmSciTech*. 2020; 5;21(6):225. doi: 10.1208/s12249-020-01744-7.  
5  
6 [6] Kathryn A Hanley The double-edged sword: How evolution can make or break a live-  
7 attenuated virus vaccine. *Evolution (N Y)*. 201;4(4):635-643. doi: 10.1007/s12052-011-  
8 0365-y.  
9  
10 [7] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and  
11 meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.  
12  
13 [8] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic  
14 reviews and meta-analyses of studies that evaluate healthcare interventions: explanation  
15 and elaboration. *BMJ* 2009;339:b2700.  
16  
17 [9] Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang  
18 L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W,  
19 Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5  
20 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human  
21 trial. *Lancet*. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3.  
22 Epub 2020 May 22. PMID: 32450106; PMCID: PMC7255193.  
23  
24 [10] Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang  
25 WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J,  
26 Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W.  
27 Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine  
28 in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled,  
29 phase 2 trial. *Lancet*. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-  
30 6736(20)31605-6. Epub 2020 Jul 20. PMID: 32702299.  
31  
32 [11] Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,  
33 Dzhharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM,  
34 Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV,  
35 Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA,  
36 Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF,  
37 Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and  
38 rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two  
39 open, non-randomised phase 1/2 studies from Russia. *Lancet*. 2020 Sep  
40 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Erratum  
41 in: *Lancet*. 2021 Jan 9;397(10269):98. PMID: 32896291; PMCID: PMC7471804.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2 [12] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy  
3 D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath  
4 P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson  
5 H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC,  
6 Pollard AJ; Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1  
7 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,  
8 randomised controlled trial. *Lancet*. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-  
9 6736(20)31604-4. Epub 2020 Jul 20. Erratum in: *Lancet*. 2020 Aug 15;396(10249):466.  
10 Erratum in: *Lancet*. 2020 Dec 12;396(10266):1884. PMID: 32702298; PMCID:  
11 PMC7445431.  
12  
13 [13] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's tool for  
14 assessing risk of bias in randomised trials. *Cochrane bias methods group; Cochrane*  
15 *statistical methods group*. *BMJ* 2011;343.  
16  
17 [14] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng  
18 HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A,  
19 Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd  
20 S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool  
21 for assessing risk of bias in randomised trials. *BMJ*. 2019 Aug 28;366:l4898. doi:  
22 10.1136/bmj.l4898. PMID: 31462531.  
23  
24 [15] Balshem H, Helfand M, Schünemann HJ, et al. Grade guidelines: 3. rating the quality  
25 of evidence. *J Clin Epidemiol* 2011;64:401–6. 10.1016/j.jclinepi.2010.07.015  
26  
27 [16] Iezadi S, Azami-Aghdash S, Ghiasi A, Rezapour A, Pourasghari H, Pashazadeh F, et  
28 al. Effectiveness of the non-pharmaceutical public health interventions against COVID-19;  
29 a protocol of a systematic review and realist review. *Plos One*. 2020; 15(9): e0239554.  
30 doi:10.1371/journal.pone.0239554  
31  
32 [17] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology,  
33 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). *JAMA*.  
34 2020. doi:10.1001/jama.2020.12839  
35  
36 [18] WHO. Coronavirus disease (COVID-19) situation report—181. Geneva: World Health  
37 Organization, 2020.  
38  
39 [19] Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status of  
40 Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019  
41 (COVID-19). *J. Microbiol. Biotechnol.* 2020;30(3):313-324  
42  
43 [20] Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an  
44 emerging coronavirus infection: advances and prospects in designing and developing  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1 vaccines, immunotherapeutics, and therapeutics. *Human Vaccines & Immunotherapeutics*.  
2 2020;1–7. doi:10.1080/21645515.2020.1735227  
3

4 [21] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety  
5 and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary  
6 report of a phase 1/2, single-blind, randomised controlled trial. *Lancet*. 2020;396(10249):  
7 467-478.  
8

9 [22] Ong E, Wong M, Huffman A and He Y. COVID-19 coronavirus vaccine design using  
10 reverse vaccinology and machine learning. *Front. Immunol*. 2020. 11:1581.  
11 doi:10.3389/fimmu.2020.01581  
12

13 [23] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for  
14 Coronavirus Disease 2019 (COVID-19). *JAMA*. 2020. doi:10.1001/jama.2020.6019.  
15

16 [24] Yuan P, Ai P, Liu Y, Ai Z, Wang Y, Cao W, Xia X, Zheng JC. Safety, Tolerability, and  
17 Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. *medRxiv*  
18 [Preprint]. 2020 Nov 4:2020.11.03.20224998. doi: 10.1101/2020.11.03.20224998. PMID:  
19 33173896; PMCID: PMC7654888.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1** Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

Figure 1 Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

168x222mm (300 x 300 DPI)





# PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	X
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	X
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	X
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	X
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and if available, provide registration information including registration number.	X
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	X
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	X
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	X
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	X
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	X
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	X
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	X
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	X
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	



# PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	X
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICCO, follow-up period) and provide the citations.	
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	X
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	X
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	X

36/bmjopen-2021-050278 on 24 February 2022. Downloaded from http://bmjopen.bmj.com/ on April 24, 2024 by guest. Protected by copyright.

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org).

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## SIDE EFFECTS OF COVID-19 VACCINES: A SYSTEMATIC REVIEW/META-ANALYSIS PROTOCOL OF RANDOMIZED TRIALS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050278.R1
Article Type:	Protocol
Date Submitted by the Author:	08-Oct-2021
Complete List of Authors:	Medeiros, Kleyton ; Universidade Federal do Rio Grande do Norte Costa, Ana Paula; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Sarmiento, Ayane Cristine ; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Freitas, Cijara Leonice; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Gonçalves, Ana; Universidade Federal do Rio Grande do Norte,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Epidemiology, Global health, Infectious diseases
Keywords:	COVID-19, IMMUNOLOGY, Adverse events < THERAPEUTICS, Clinical trials < THERAPEUTICS, TOXICOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **SIDE EFFECTS OF COVID-19 VACCINES: A SYSTEMATIC REVIEW/META-**  
4 **ANALYSIS PROTOCOL OF RANDOMIZED TRIALS**  
5  
6  
7  
8  
9

10 Kleyton Santos Medeiros<sup>1,2#</sup>, Ana Paula Ferreira Costa<sup>1#</sup>, Ayane Cristine Alves  
11 Sarmiento<sup>1#</sup>, Cijara Leonice Freitas, Ana Katherine Gonçalves<sup>1,3\*</sup>  
12  
13  
14

15 <sup>1</sup> Health Sciences Postgraduate Program, Federal University of Rio Grande do  
16 Norte (UFRN), Natal, RN, Brazil. Email: kleyton\_medeiros@hotmail.com / ana-  
17 paula-rf@hotmail.com / ayane\_cris@hotmail.com / cijara\_enfer@hotmail.com  
18  
19

20 <sup>2</sup> Intituto de Ensino, Pesquisa e Inovação. Liga Contra o Câncer, Natal, RN,  
21 Brazil.  
22

23 <sup>3</sup> Department of obstetrics and gynaecology, Federal University of Rio Grande do  
24 Norte (UFRN), Natal, RN, Brazil. Email: anakatherine\_ufrnet@yahoo.com.br  
25  
26  
27

28  
29 # KSM, ACAS, APFC are considered first authors.  
30  
31

32 \*Correspondence  
33

34 Ana Katherine Gonçalves, Major Laurentino de Moraes St 1218/1301, Natal, RN,  
35 Brazil. Email: anakatherine\_ufrnet@yahoo.com.br  
36

37 ORCID ID: <https://orcid.org/0000-0002-8351-5119>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

### Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a large number of global coronavirus disease 2019 (COVID-19) cases. Strategies such as social isolation, personal hygiene, and frequent hand washing have been implemented; however, a protective vaccine is required to achieve sufficient herd immunity to SARS-CoV-2 infection to ultimately control the COVID-19 pandemic. To meet the urgent need for a vaccine, a reduction in the development schedule has been proposed, from 10–15 years to 1–2 years. For this reason, this systematic review and meta-analysis protocol aims to compare the side effects, safety, and toxicity of COVID-19 vaccines available globally, including their combinations.

### Methods and analysis

We will select randomized controlled trial (RCT)-type studies that evaluate the side effects of the COVID-19 vaccine. PubMed, Web of Science, Embase, CINAHAL, PsycINFO, LILACS, SCOPUS, ClinicalTrials.gov, International Clinical Trials Registry Platform (ICTRP), medRxiv.org, biorxiv.org, preprints.org and the Cochrane Library will be searched for eligible studies until December 2021. Three reviewers will independently screen and select studies, assess methodological quality, and extract data. A meta-analysis will be performed, if possible, and the Grading of Recommendations Assessment Development and Evaluation (GRADE) Summary of Findings will be presented.

### Ethics and dissemination

This study will review published data, and thus it is unnecessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal.

**Systematic review registration:** CRD42021231101.

**Keywords:** COVID-19; SARS-Cov-2; COVID-19 vaccine; SARS-CoV-2 vaccine

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- The results obtained in this systematic review will, through evidence-based medicine, indicate the rates of adverse reactions (local and systemic) of COVID-19 vaccines.
- Four authors, KSM, APFC, ACAS, and CLF will select the articles independently, using titles and abstracts.
- To the best of our knowledge, there are no existing reviews regarding the side effects of COVID-19 vaccines.
- Potential limitations include a great diversity of existing vaccines, still being tested, and heterogeneity of systemic and local adverse events.

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a large number of global coronavirus disease (COVID-19) cases. It is a highly transmissible virus among humans that has become a significant public health issue [1]. Symptoms include fever, dry cough, fatigue, shortness of breath, chills, muscle pain, headache, gastric disorders, and weight loss, often leading to death [2].

Strategies such as social isolation, personal hygiene, and frequent hand washing have been implemented; however, a protective vaccine is required to achieve sufficient herd immunity to SARS-CoV-2 infection to ultimately control the COVID-19 pandemic [3]. To meet the urgent need for a vaccine, a reduction in the development schedule has been proposed, from 10–15 years to 1–2 years [4].

SARS-CoV2 is an RNA virus with a high mutation rate, that on the envelope surface has three important structural proteins that can be identified: spike protein (S), envelope protein (E), and membrane protein (M). Most innovative vaccines have focused their efforts on inducing an immune response against the Spike protein. Altogether more than 40 vaccines are now under clinical evaluation, ten of them are in Phase III clinical trials, three of them have closed Phase III with positive results. Attenuated virus vaccines are based on weakened microorganisms, effective in stimulating the immune system. The inactivated ones (dead microorganisms) are more stable than the attenuated ones, but they have a short duration of immunological memory that requires the association of adjuvants. mRNA vaccines are stable – and can be easily

1  
2  
3 produced in large quantities. Vaccines against COVID-19 differ in composition  
4 and mechanism of action, which may be relevant for their safety and efficacy,  
5 being essential for the success and eradication of this infection [5, 6]. The viral  
6 vector (mRNA) vaccine encodes full-length S protein ectodomains of SARS-CoV-  
7 2, which contains both T and B cell epitopes that can induce cellular and humoral  
8 immune responses against viral infection [7].  
9

10  
11  
12  
13 Assessing the safety, efficacy and side effects of the vaccine is urgently  
14 needed, and has been heavily scrutinized by leading medical agencies around  
15 the world, like the Centers for Disease Control and Prevention (CDC) and Food  
16 & Drug Administration (FDA). Developing any vaccine needs to ensure that safety  
17 risks are identified and quantified against potential benefits. Among the potential  
18 risks raised in the context of COVID-19, vaccine development is the security and  
19 effectiveness of immune responses elicited by a vaccine. Here, this systematic  
20 review protocol aims to assess the side effects, safety, and toxicity of vaccines  
21 against COVID-19.  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **OBJECTIVES**

31  
32 This systematic review and meta-analysis protocol aims to compare the  
33 side effects, safety, and toxicity of COVID-19 vaccines available globally,  
34 including their combination.  
35  
36  
37  
38

## 39 **Review question**

40  
41 What are the rates of adverse reactions (local and systemic) to COVID-19  
42 vaccines?  
43  
44  
45

## 46 **METHODS AND ANALYSIS**

47  
48 The meta-analysis protocol follows the Preferred Reporting Items for  
49 Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines [8, 9].  
50 This protocol is registered with the International Prospective Register of  
51 Systematic Reviews (CRD42021231101).  
52  
53  
54  
55

## 56 **Eligibility criteria**

57  
58 The inclusion criteria involved (1) randomized controlled trial (RCT)-type  
59 studies that evaluated the side effects of the COVID-19 vaccine; (2) experiments  
60

1  
2  
3 involving human beings; (3) studies evaluating the safety, immunogenicity, and  
4 efficacy parameters of the vaccines; (4) studies that presented similar vaccination  
5 protocols; (5) studies published since January 2020 until December 2021; and  
6  
7 (6) studies published in any language.  
8  
9

10 The exclusion criteria were as follows: (1) observational studies, and (2)  
11 case reports, meeting abstracts, review papers, and commentaries.  
12  
13

### 14 **Patients, intervention, comparison, outcome strategy, and types of** 15 **studies**

- 16 • Patients: Healthy adults aged 18 years or older who were HIV-negative and  
17 previously SARS-CoV-2 infection-free
- 18 • Intervention: COVID-19 vaccine or a combination of vaccines against COVID-  
19 19.
- 20 • Comparator/control: Placebo
- 21 • Outcome: safety, tolerability, and immunogenicity of the COVID-19 vaccine or  
22 the combination of vaccines against COVID-19
- 23 • Types of studies: randomized controlled trials (RCT)
- 24  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Information sources**

35  
36  
37 The following databases will be searched: Medline/PubMed, Web of  
38 Science, Embase, CINAHAL, PsycINFO, Latin American and Caribbean Health  
39 Sciences Literature (LILACS), SCOPUS, ClinicalTrials.gov, International Clinical  
40 Trials Registry Platform (ICTRP), medRxiv.org, biorxiv.org, preprints.org and  
41 Cochrane Central Controlled Trials Registry. Furthermore, eligible studies may  
42 also be selected from the reference lists of retrieved articles.  
43  
44  
45  
46  
47  
48  
49

### 50 **Patient and public involvement**

51 The individual patient data will not be presented. A literature search will  
52 be carried out from defined databases. No patient will be involved in the study  
53 planning, application process during neither the analysis nor dissemination of  
54 results.  
55  
56  
57  
58  
59

### 60 **Search strategy**



Our keyword search will be based on Medical Subject Headings (MeSH) according to the following combination: (COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR coronavirus) AND (vaccines OR vaccination OR COVID-19 vaccine OR SARS-CoV-2 vaccine OR BNT162 vaccine OR mRNA-1273 vaccine OR Covid-19 aAPC vaccine OR INO-4800 vaccine OR LV-SMENP-DC COVID-19 vaccine OR Ad5-nCoV vaccine OR ChAdOx1 COVID-19 vaccine OR MNA SARS-CoV-2 S1 subunit vaccines OR PittCoVacc OR Inactivated novel coronavirus 2019-CoV vaccine Vero cells OR Inactivated Vaccines OR SARS-CoV-2 inactivated vaccines OR Viral Vaccines OR Gam-COVID-Vac vaccine OR Ad26.COVS vaccine OR EpiVacCorona vaccine) AND (Toxicity OR Vaccine Immunogenicity OR side effects OR adverse events) AND (randomized controlled trial OR double blind method OR clinical trial) (Table 1). A list of vaccines available at WHO was also used.

**Table 1 Medline search strategy**

Search items

1	COVID-19
2	SARS-CoV-2
3	2019-nCoV
4	Coronavirus
5	Or/1-4
6	vaccines
7	vaccination
8	COVID-19 vaccine
9	SARS-CoV-2 vaccine
10	BNT162 vaccine
11	mRNA-1273 vaccine
12	COVID-19 aAPC vaccine
13	INO-4800 vaccine
14	LV-SMENP-DC COVID-19 vaccine
15	Ad5-nCoV vaccine
16	ChAdOx1 COVID-19 vaccine
17	MNA SARS-CoV-2 S1 subunit vaccines

1	
2	
3	18 PittCoVacc
4	
5	19 Inactivated novel coronavirus 2019-CoV vaccine Vero cells
6	
7	20 Inactivated Vaccines
8	
9	21 SARS-CoV-2 inactivated vaccines
10	
11	22 Viral Vaccines
12	
13	23 Gam-COVID-Vac vaccine
14	
15	24 Ad26.COVS vaccine
16	
17	25 EpiVacCorona vaccine
18	
19	26 Or/6-25
20	
21	27 Toxicity
22	
23	28 Vaccine Immunogenicity
24	
25	29 side effects
26	
27	30 adverse events
28	
29	31 Or/27-30
30	
31	32 randomized controlled trial
32	
33	33 double-blind method
34	
35	34 clinical trial
36	
37	35 Or/32-34
38	
39	36 5 AND 26 AND 31 AND 35

### Study records

Four researchers (KSM, APFC, ACAS, and CLF) performed the selection of the studies of interest. Titles and abstracts will be read independently, and duplicate studies will be excluded. The same authors analyzed the selected texts to assess compliance with the inclusion criteria. A fifth reviewer, AKG, solves the discrepancies. The flowchart of this study is shown in Figure 1.

### [Insert Figure 1]

**Figure 1** Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

### Data collection process and management

1  
2  
3 A standardized data extraction form was developed and tested. Data from  
4 each included study will be extracted independently by two reviewers (ACAS and  
5 APFC), and any subsequent discrepancies will be resolved through discussion  
6 with a third reviewer (AKG). The data extracted will include information on  
7 authors, the year of publication, study location, type of study, main objectives,  
8 population, type of vaccine, follow-up of participants, rates of systemic events,  
9 gastrointestinal (GI) symptoms, injection site-related adverse effects, and serious  
10 vaccine-related adverse events (Table 2). Furthermore, participant  
11 characteristics (e.g., mean age, gender), and results for immunogenicity will be  
12 collected.  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 **Table 2** Adverse events of COVID-19 vaccines

23 Adverse Events

24 Systemic events reactions (10, 11)	25 Fever or hyperthermia or feverish, 26 headaches, fatigue, vomiting, diarrhea, 27 muscle pain, joint pain, cough, nausea, 28 dyspnea, appetite impaired, dizziness, 29 mucosal abnormality, pruritus [10, 11], 30 hypersensitivity, syncope [10], asthenia, 31 rhinorrhea, malaise, sore throat (throat 32 irritation), pain in the oropharynx 33 (pharyngalgia), hives, nasal congestion 34 [12, 13].
35 Injection site adverse reactions (10- 36 12)	37 Pain, induration, redness or erythema, 38 swelling, itch, and muscular weakness 39 [10-12].
40 Serious vaccine-related adverse 41 event	42 Deaths, hospitalisation [13], Thrombotic 43 complications [14, 15].

44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 The study authors will be contacted in case of missing data and/or to  
55 resolve any uncertainties. In addition, any additional information will be recorded.  
56 All data entries will be checked twice. If we find a set of articles with similar  
57 characteristics based on the information in the data extraction table, we will  
58  
59  
60

1  
2  
3 perform a meta-analysis using a random-effects model. If there is data that is not  
4 clear in some articles, the corresponding author will be contacted for possible  
5 clarification.  
6  
7  
8  
9

### 10 **Risk of bias in individual studies**

11 Three authors, KSM, ACAS, and APFC, will independently assess the risk  
12 of bias in the eligible studies using the Cochrane risk-of-bias tool [16]. The Risk  
13 of Bias 2 (RoB 2) tool [17] will be used to assess the risk of bias. Bias is assessed  
14 as a judgment (high, low, or unclear) for individual elements from five domains  
15 (selection, performance, attrition, reporting, and others).  
16  
17  
18  
19  
20  
21

### 22 **Data synthesis and analysis**

23 Data will be entered into the Review Manager software (RevMan5.2.3).  
24 This software allows the user to enter protocols; complete reviews; include text,  
25 characteristics of the studies, comparison tables, and study data; and perform  
26 meta-analyses. For dichotomous outcomes, we extracted or calculated the OR  
27 and 95% CI for each study. In case of heterogeneity ( $I^2 \geq 50\%$ ), the random-  
28 effects model will be used to combine the studies to calculate the OR and 95% CI,  
29 using the DerSimonian–Laird algorithm.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

### 42 **Meta-bias**

43 To grade the strength of evidence from the included data, we will use the  
44 Grading of Recommendation Assessment, Development, and Evaluation  
45 (GRADE) [18] approach. The summary of the assessment will be incorporated  
46 into broader measurements to ensure the judgment of the risk of bias,  
47 consistency, directness, and precision. The quality of the evidence will be  
48 assessed based on the risk of bias, indirectness, inconsistency, imprecision, and  
49 publication bias.  
50  
51  
52  
53  
54  
55  
56

## 57 **DISCUSSION**

1  
2  
3 The COVID-19 pandemic represents one of the most significant global  
4 public health crises of this generation. Lockdown, quarantine, contact tracing, and  
5 case isolation are suggested as effective interventions to control the epidemic;  
6 however, they may present different results in different contexts because of the  
7 specific features of the COVID-19. The lack of implementation of continued  
8 interventions or effective treatments further contributes to discovering and using  
9 effective and safe vaccines [19,20].

15 For all these reasons, scientists worldwide entered a race to find a vaccine  
16 candidate useful in fighting the new coronavirus pandemic. Nevertheless, it is  
17 essential to note that a vaccine's production is not easy and quick. Before being  
18 released to the population, a vaccine must go through three phases of clinical  
19 trials that prove its safety and effectiveness. More volunteers are recruited at  
20 each stage, and the researchers analyze the test results to ensure that a vaccine  
21 can be licensed [21-23].

27 One hundred seventy-three vaccines were in preclinical development and  
28 64 in clinical trials until January 20th, 2021. On December 31, 2020, the World  
29 Health Organization (WHO) listed the mRNA vaccine against COVID-19 for  
30 emergency use, making this Pfizer/BioNTech immunizer the first to receive WHO  
31 emergency validation from the beginning outbreak. Already, in January 2021  
32 emergency approval was granted to nine vaccines by regulatory authorities in  
33 different parts of the world [19, 24].

39 With the starting vaccination, several studies were carried out to ascertain  
40 the safety of these vaccines, since they were produced in record time [25-27].  
41 Currently, one systematic review about the thematic showed that of eleven  
42 published clinical trials of COVID-19 vaccines included in study, adverse  
43 reactions reported were considered mild to moderate with few severe reactions  
44 which were unrelated to the test vaccine. Common adverse events were pain at  
45 the site of injection, fever, myalgia, fatigue, and headache. Serious adverse  
46 events were reported in four trials: COVID-19 Vaccine AstraZeneca (AZD1222)—  
47 168 SAE with only three related to the vaccine; Ad26.COV2.S- fou with none  
48 related to the testing vaccine; five with Comirnaty (BNT162b1) and one with  
49 Covaxin (BBV152) vaccine [24].

58 One limitation about the COVID-19 vaccine safety tested until now is that  
59 clinical trials of the safety and effectiveness have had low inclusion of vulnerable  
60

1  
2  
3 groups, for example, older persons, the first population to receive the whole  
4 vaccine. That's why pharmacovigilance post-marketing is necessary to  
5 surveillance new drugs, as a critical aspect of evaluating medicine safety and  
6 effectiveness, particularly in risk groups.  
7  
8  
9

10 Other prevention approaches are likely to emerge in the coming months,  
11 including monoclonal antibodies, hyper-immune globulin, and convalescent titer.  
12 If proven effective, these approaches could be used in high-risk individuals,  
13 including health care workers, other essential workers, and older adults [28,29].  
14 It is essential to maintain protective measures such as washing hands frequently  
15 with soap and water or gel alcohol and covering the mouth with a forearm when  
16 coughing or sneezing.  
17  
18  
19  
20  
21

22 For all the reasons mentioned above, this review is necessary and  
23 essential. The latter is a well-defined protocol registered with Prospero, well  
24 planned to include the largest possible number of vaccines, a significant number  
25 of vaccinated patients, thus providing safe and reliable results regarding the use  
26 of vaccines.  
27  
28  
29  
30  
31

## 32 **CONCLUSION**

33  
34 During the COVID-19 pandemic, humanity has experienced the most severe  
35 health crisis in recent years. It's important to remember that, although the COVID-  
36 19 vaccines are being widely used a lot places the world, the Emergency Use  
37 Approval is different from marketing approval, and although the clinical trials  
38 demonstrated good results until now, the study of the efficacy and safety of these  
39 vaccines, included safety data from larger sample size and of longer duration, the  
40 is extremely important for user security of COVID-19 vaccines.  
41  
42  
43  
44  
45  
46  
47  
48

## 49 **Ethics and Dissemination**

50  
51 This study will review published data, and thus it is unnecessary to obtain ethical  
52 approval. The findings of this systematic review will be published in a peer-  
53 reviewed journal.  
54  
55  
56  
57  
58  
59

## 60 **Contributors**

1  
2  
3 KSM, ACAS, and APFC contributed to the design of this review. KSM and ACAS  
4 drafted the protocol manuscript, and APFC and AKG revised it. KSM, AKG, and  
5 APFC developed the search strategies, and KSM, CLF, and ACAS will implement  
6 them. KSM, CLF, ACAS, and APFC will track potential studies, extract data, and  
7 assess quality. In cases of disagreement between the data extractors, AKG will  
8 advise on the methodology and will work as a referee. KSM will complete the data  
9 synthesis. All authors will approve the final version for publication.  
10  
11  
12  
13  
14  
15  
16

### 17 **Funding**

18 The authors have not declared a specific grant for this research from any funding  
19 agency in the public, commercial, or not-for-profit sectors.  
20  
21  
22  
23

### 24 **Competing interests**

25 None declared.  
26  
27  
28  
29  
30

### 31 **REFERENCES**

- 32  
33  
34 [1] Michael A Johansson, Talia M Quandelacy, Sarah Kada, et al. SARS-CoV-2  
35 Transmission From People Without COVID-19 Symptoms. *JAMA Netw Open*.  
36 2021 Jan 4;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057.  
37  
38 [2] Simran Preet Kaur, Vandana Gupta. COVID-19 Vaccine: A comprehensive  
39 status report. *Virus Res*. 2020;15;288:198114. doi:  
40 10.1016/j.virusres.2020.198114.  
41  
42 [3] Barney S Graham. Rapid COVID-19 vaccine development. *Science*.  
43 2020;368(6494):945-946. doi: 10.1126/science.abb8923.  
44  
45 [4] Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, Matthew S Miller,  
46 Brian D Lichty, Zhou Xing. Immunological considerations for COVID-19 vaccine  
47 strategies. *Nat Rev Immunol*. 2020;20(10):615-632. doi: 10.1038/s41577-020-  
48 00434-6.  
49  
50 [5] Guido Forni, Alberto Mantovani. COVID-19 vaccines: where we stand and  
51 challenges ahead. *Cell Death Differ*. 2021 Feb;28(2):626-639. doi:  
52 10.1038/s41418-020-00720-9.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 [6] Pollard AJ. Notice of addendum to article reporting Oxford trial of  
4 ChAdOx1nCoV-19 vaccine. *Lancet*. 2020;396:e89. doi: 10.1016/S0140-  
5 6736(20)32467-3.  
6  
7

8 [7] Miao Cao, Xiaojie Su, Shibo Jiang. Broad-Spectrum Anti-coronavirus Vaccines  
9 and Therapeutics to Combat the Current COVID-19 Pandemic and Future  
10 Coronavirus Disease Outbreaks. *Stem Cell Reports*. 2021 Mar 9; 16(3): 398–  
11 411. doi: 10.1016/j.stemcr.2020.12.010  
12  
13

14 [8] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic  
15 reviews and meta-analyses: the PRISMA statement. *PLoS Med*  
16 2009;6:e1000097.  
17  
18

19 [9] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting  
20 systematic reviews and meta-analyses of studies that evaluate healthcare  
21 interventions: explanation and elaboration. *BMJ* 2009;339:b2700.  
22  
23

24 [10] Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang  
25 Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ,  
26 Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a  
27 recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,  
28 open-label, non-randomised, first-in-human trial. *Lancet*. 2020 Jun  
29 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020  
30 May 22. PMID: 32450106; PMCID: PMC7255193.  
31  
32

33 [11] Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang  
34 L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y,  
35 Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW,  
36 Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus  
37 type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a  
38 randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020 Aug  
39 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul  
40 20. PMID: 32702299.  
41  
42

43 [12] Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,  
44 Dzhharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG,  
45 Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA,  
46 Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV,  
47 Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA,  
48 Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV,  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5  
4 vector-based heterologous prime-boost COVID-19 vaccine in two formulations:  
5 two open, non-randomised phase 1/2 studies from Russia. *Lancet*. 2020 Sep  
6 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep  
7 4. Erratum in: *Lancet*. 2021 Jan 9;397(10269):98. PMID: 32896291; PMCID:  
8 PMC7471804.  
9

10  
11 [13] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S,  
12 Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman  
13 AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock  
14 KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C,  
15 Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine  
16 Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine  
17 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,  
18 randomised controlled trial. *Lancet*. 2020 Aug 15;396(10249):467-478. doi:  
19 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: *Lancet*. 2020  
20 Aug 15;396(10249):466. Erratum in: *Lancet*. 2020 Dec 12;396(10266):1884.  
21 PMID: 32702298; PMCID: PMC7445431.  
22

23 [14] M. Porres-Aguilar, M.C. Guerrero-de León, F.A. Grimaldo-Gómez, R  
24 Izaguirre-Ávila, A Cabrera-Rayó, L.E. Santos-Martínez, et al. Thrombotic  
25 complications in severe COVID-19: focus on venous thromboembolism,  
26 thromboprophylaxis and anticoagulation. *Cir Cir*, 89 (2021), pp. 115-119.  
27 <http://dx.doi.org/10.24875/CIRU.20000879>  
28

29 [15] Mateo Porres-Aguilar, Alejandro Lazo-Langner, Arturo Panduro, Misael  
30 Uribe. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An  
31 emerging cause of splanchnic vein thrombosis. *Ann Hepatol*. Jul-Aug  
32 2021;23:100356. doi: 10.1016/j.aohep.2021.100356.  
33

34 [14] Higgins JP, Altman DG , Gøtzsche PC , et al . The Cochrane collaboration's  
35 tool for assessing risk of bias in randomised trials. *Cochrane bias methods group*;  
36 *Cochrane statistical methods group*. *BMJ* 2011;343.  
37

38 [15] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates  
39 CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell  
40 S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T,  
41 McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR,  
42 Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 randomised trials. *BMJ*. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898. PMID:  
4 31462531.

5  
6 [16] Balshem H, Helfand M, Schünemann HJ, et al. Grade guidelines: 3. rating  
7 the quality of evidence. *J Clin Epidemiol* 2011;64:401–6.  
8 10.1016/j.jclinepi.2010.07.015

9  
10 [17] Iezadi S, Azami-Aghdash S, Ghiasi A, Rezapour A, Poursaghari H,  
11 Pashazadeh F, et al. Effectiveness of the non-pharmaceutical public health  
12 interventions against COVID-19; a protocol of a systematic review and realist  
13 review. *Plos One*. 2020; 15(9): e0239554. doi:10.1371/journal.pone.0239554

14  
15 [18] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.  
16 Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus  
17 Disease 2019 (COVID-19). *JAMA*. 2020. doi:10.1001/jama.2020.12839

18  
19 [19] WHO. Coronavirus disease (COVID-19) situation report—181. Geneva:  
20 World Health Organization, 2020.

21  
22 [20] Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status  
23 of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus  
24 Disease 2019 (COVID-19). *J. Microbiol. Biotechnol.* 2020;30(3):313-324

25  
26 [21] Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-  
27 19, an emerging coronavirus infection: advances and prospects in designing and  
28 developing vaccines, immunotherapeutics, and therapeutics. *Human Vaccines &*  
29 *Immunotherapeutics*. 2020;1–7. doi:10.1080/21645515.2020.1735227

30  
31 [22] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S,  
32 et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against  
33 SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised  
34 controlled trial. *Lancet*. 2020;396(10249): 467-478.

35  
36 [23] Ong E, Wong M, Huffman A and He Y. COVID-19 coronavirus vaccine design  
37 using reverse vaccinology and machine learning. *Front. Immunol.* 2020. 11:1581.  
38 doi:10.3389/fimmu.2020.01581

39  
40 [24] Kaur RJ, Dutta S, Bhardwaj P, Charan J, Sameer Dhingra S, Mitra P, et al.  
41 Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.  
42 *Ind J Clin Biochem*. 2021. [https://link.springer.com/article/10.1007/s12291-021-](https://link.springer.com/article/10.1007/s12291-021-00968-z)  
43 [00968-z](https://link.springer.com/article/10.1007/s12291-021-00968-z)

44  
45 [25] Chen J, Cai Y, Chen Y, P. Williams A, Gao Y, Zeng J. Nervous and Muscular  
46 Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


1  
2  
3 Analysis of Clinical Trials. *Vaccines*. 2021; 9:939.  
4 <https://doi.org/10.3390/vaccines9080939>.

5  
6 [26] Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al.  
7 Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on  
8 covid-19 related symptoms, hospital admissions, and mortality in older adults in  
9 England: test negative case-control study. *BMJ*. 2021;373:n1088. doi:  
10 10.1136/bmj.n1088  
11  
12

13  
14 [27] Iheanacho CO, Eze UIH, Adida EA. A systematic review of effectiveness of  
15 BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the  
16 general population. *Bull Natl Res Cent*. 2021;45:150.  
17  
18

19  
20 [28] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic  
21 Treatments for Coronavirus Disease 2019 (COVID-19). *JAMA*. 2020.  
22 doi:10.1001/jama.2020.6019.  
23  
24

25  
26 [29] Yuan P, Ai P, Liu Y, Ai Z, Wang Y, Cao W, Xia X, Zheng JC. Safety,  
27 Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review  
28 and Meta-Analysis. *medRxiv [Preprint]*. 2020 Nov 4:2020.11.03.20224998. doi:  
29 10.1101/2020.11.03.20224998. PMID: 33173896; PMCID: PMC7654888.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1** Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

Figure 1 Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

168x222mm (300 x 300 DPI)

**PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\***

Section and topic	Item No	Checklist item	
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	01
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	-
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	02
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	01
	3b	Describe contributions of protocol authors and identify the guarantor of the review	01
Contributions			
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	-
Support:			
Sources	5a	Indicate sources of financial or other support for the review	x
Sponsor	5b	Provide name for the review funder and/or sponsor	x
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	-
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	03
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	04
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	05
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	05

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	06
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	08
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	08
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	09
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	09
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	09
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	09
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	10
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	10
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	10
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	10

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

# BMJ Open

## SIDE EFFECTS OF COVID-19 VACCINES: A SYSTEMATIC REVIEW/META-ANALYSIS PROTOCOL OF RANDOMIZED TRIALS

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050278.R2
Article Type:	Protocol
Date Submitted by the Author:	06-Jan-2022
Complete List of Authors:	Medeiros, Kleyton ; Universidade Federal do Rio Grande do Norte Costa, Ana Paula; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Sarmiento, Ayane Cristine ; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Freitas, Cijara Leonice; Federal University of Rio Grande do Norte, Health Sciences Postgraduate Program Gonçalves, Ana; Universidade Federal do Rio Grande do Norte,
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	Epidemiology, Global health, Infectious diseases
Keywords:	COVID-19, IMMUNOLOGY, Adverse events < THERAPEUTICS, Clinical trials < THERAPEUTICS, TOXICOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **SIDE EFFECTS OF COVID-19 VACCINES: A SYSTEMATIC REVIEW/META-**  
4 **ANALYSIS PROTOCOL OF RANDOMIZED TRIALS**  
5  
6  
7  
8  
9

10 Kleyton Santos Medeiros<sup>1,2#</sup>, Ana Paula Ferreira Costa<sup>1#</sup>, Ayane Cristine Alves  
11 Sarmiento<sup>1#</sup>, Cijara Leonice Freitas, Ana Katherine Gonçalves<sup>1,3\*</sup>  
12  
13  
14

15 <sup>1</sup> Health Sciences Postgraduate Program, Federal University of Rio Grande do  
16 Norte (UFRN), Natal, RN, Brazil. Email: kleyton\_medeiros@hotmail.com / ana-  
17 paula-rf@hotmail.com / ayane\_cris@hotmail.com / cijara\_enfer@hotmail.com  
18  
19

20 <sup>2</sup> Instituto de Ensino, Pesquisa e Inovação. Liga Contra o Câncer, Natal, RN,  
21 Brazil.  
22

23 <sup>3</sup> Department of Obstetrics and Gynaecology, Federal University of Rio Grande  
24 do Norte (UFRN), Natal, RN, Brazil. Email: anakatherine\_ufrnet@yahoo.com.br  
25  
26  
27

28  
29 # KSM, ACAS, APFC are considered first authors.  
30  
31

32 \*Correspondence  
33

34 Ana Katherine Gonçalves, Major Laurentino de Moraes St 1218/1301, Natal, RN,  
35 Brazil. Email: anakatherine\_ufrnet@yahoo.com.br  
36

37 ORCID ID: <https://orcid.org/0000-0002-8351-5119>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ABSTRACT

### Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a large number of global coronavirus disease 2019 (COVID-19) cases. Strategies such as social isolation, personal hygiene, and frequent hand washing have been implemented; however, a protective vaccine is required to achieve sufficient herd immunity to SARS-CoV-2 infection to ultimately control the COVID-19 pandemic. To meet the urgent need for a vaccine, a reduction in the development schedule has been proposed, from 10–15 years to 1–2 years. For this reason, this systematic review and meta-analysis protocol aims to compare the side effects, safety, and toxicity of COVID-19 vaccines available globally, including their combinations.

### Methods and analysis

We will select randomized controlled trial (RCT)-type studies that evaluate the side effects of the COVID-19 vaccine. PubMed, Web of Science, Embase, CINAHAL, PsycINFO, LILACS, SCOPUS, ClinicalTrials.gov, International Clinical Trials Registry Platform (ICTRP), medRxiv.org, biorxiv.org, preprints.org and the Cochrane Library will be searched for eligible studies until December 2021. Three reviewers will independently screen and select studies, assess methodological quality, and extract data. A meta-analysis will be performed, if possible, and the Grading of Recommendations Assessment Development and Evaluation (GRADE) Summary of Findings will be presented.

### Ethics and dissemination

This study will review published data, and thus it is unnecessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal.

**Systematic review registration:** CRD42021231101.

**Keywords:** COVID-19; SARS-Cov-2; COVID-19 vaccine; SARS-CoV-2 vaccine

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- Four authors, KSM, APFC, ACAS, and CLF will select the articles independently, using titles and abstracts.
- To the best of our knowledge, there are no existing reviews regarding the side effects of COVID-19 vaccines.
- The DerSimonian and Laird (1986) (DL) method may underestimate the true between-study variance, potentially producing overly narrow confidence intervals (CIs) for the mean effect. This fact is a limitation, so, the collection of studies will be done with care and the assumptions of the analytical methods will be assessed.

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a large number of global coronavirus disease (COVID-19) cases. It is a highly transmissible virus among humans that has become a significant public health issue [1]. Symptoms include fever, dry cough, fatigue, shortness of breath, chills, muscle pain, headache, gastric disorders, and weight loss, often leading to death [2].

Strategies such as social isolation, personal hygiene, and frequent hand washing have been implemented; however, a protective vaccine is required to achieve sufficient herd immunity to SARS-CoV-2 infection to ultimately control the COVID-19 pandemic [3]. To meet the urgent need for a vaccine, a reduction in the development schedule has been proposed, from 10–15 years to 1–2 years [4].

SARS-CoV2 is an RNA virus with a high mutation rate, that on the envelope surface has three important structural proteins that can be identified: spike protein (S), envelope protein (E), and membrane protein (M). Most innovative vaccines have focused their efforts on inducing an immune response against the Spike protein. Attenuated virus vaccines are based on weakened microorganisms, effective in stimulating the immune system. The inactivated ones (dead microorganisms) are more stable than the attenuated ones, but they have a short duration of immunological memory that requires the association of adjuvants. mRNA vaccines are stable – and can be easily produced in large

1  
2  
3 quantities. Vaccines against COVID-19 differ in composition and mechanism of  
4 action, which may be relevant for their safety and efficacy, being essential for the  
5 success and eradication of this infection [5, 6]. The viral vector (mRNA) vaccine  
6 encodes full-length S protein ectodomains of SARS-CoV-2, which contains both  
7 T and B cell epitopes that can induce cellular and humoral immune responses  
8 against viral infection [7].  
9

10  
11  
12  
13 Assessing the safety, efficacy and side effects of the vaccine is urgently  
14 needed, and has been heavily scrutinized by leading medical agencies around  
15 the world, like the Centers for Disease Control and Prevention (CDC) and Food  
16 & Drug Administration (FDA). Developing any vaccine needs to ensure that safety  
17 risks are identified and quantified against potential benefits. Among the potential  
18 risks raised in the context of COVID-19, vaccine development is the security and  
19 effectiveness of immune responses elicited by a vaccine. Here, this systematic  
20 review protocol aims to assess the side effects, safety, and toxicity of vaccines  
21 against COVID-19.  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **OBJECTIVES**

31  
32 This systematic review and meta-analysis protocol aims to compare the  
33 side effects, safety, and toxicity of COVID-19 vaccines available globally,  
34 including their combination.  
35  
36  
37  
38

## 39 **Review question**

40  
41 What are the rates of adverse reactions (local and systemic) to COVID-19  
42 vaccines?  
43  
44  
45

## 46 **METHODS AND ANALYSIS**

47  
48 The meta-analysis protocol follows the Preferred Reporting Items for  
49 Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) guidelines [8, 9].  
50 This protocol is registered with the International Prospective Register of  
51 Systematic Reviews (CRD42021231101).  
52  
53  
54  
55

## 56 **Eligibility criteria**

57  
58 The inclusion criteria involved (1) randomized controlled trial (RCT)-type  
59 studies that evaluated the side effects of the COVID-19 vaccine; (2) experiments  
60

1  
2  
3 involving human beings; (3) studies evaluating the safety, immunogenicity, and  
4 efficacy parameters of the vaccines; (4) studies that presented similar vaccination  
5 protocols; (5) studies published since January 2020 until December 2021; and  
6  
7 (6) studies published in any language.  
8  
9

10 The exclusion criteria were as follows: (1) observational studies, and (2)  
11 case reports, meeting abstracts, review papers, and commentaries.  
12  
13  
14

### 15 **Patients, intervention, comparison, outcome strategy, and types of** 16 **studies**

- 17 • Patients: Healthy adults aged 18 years or older who were HIV-negative and  
18 previously SARS-CoV-2 infection-free
- 19 • Intervention: COVID-19 vaccine or a combination of vaccines against COVID-  
20 19.
- 21 • Comparator/control: Placebo
- 22 • Outcome: safety, tolerability, and immunogenicity of the COVID-19 vaccine or  
23 the combination of vaccines against COVID-19
- 24 • Types of studies: randomized controlled trials (RCT)
- 25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 **Information sources**

35  
36  
37 The following databases will be searched: Medline/PubMed, Web of  
38 Science, Embase, CINAHAL, PsycINFO, Latin American and Caribbean Health  
39 Sciences Literature (LILACS), SCOPUS, ClinicalTrials.gov, International Clinical  
40 Trials Registry Platform (ICTRP), medRxiv.org, biorxiv.org, preprints.org and  
41 Cochrane Central Controlled Trials Registry. Furthermore, eligible studies may  
42 also be selected from the reference lists of retrieved articles.  
43  
44  
45  
46  
47  
48  
49

### 50 **Patient and public involvement**

51 The individual patient data will not be presented. A literature search will  
52 be carried out from defined databases. No patient will be involved in the study  
53 planning, application process during neither the analysis nor dissemination of  
54 results.  
55  
56  
57  
58  
59  
60

### **Search strategy**

Our keyword search will be based on Medical Subject Headings (MeSH) according to the following combination: (COVID-19 OR SARS-CoV-2 OR 2019-nCoV OR coronavirus) AND (vaccines OR vaccination OR COVID-19 vaccine OR SARS-CoV-2 vaccine OR BNT162 vaccine OR mRNA-1273 vaccine OR Covid-19 aAPC vaccine OR INO-4800 vaccine OR LV-SMENP-DC COVID-19 vaccine OR Ad5-nCoV vaccine OR ChAdOx1 COVID-19 vaccine OR MNA SARS-CoV-2 S1 subunit vaccines OR PittCoVacc OR Inactivated novel coronavirus 2019-CoV vaccine Vero cells OR Inactivated Vaccines OR SARS-CoV-2 inactivated vaccines OR Viral Vaccines OR Gam-COVID-Vac vaccine OR Ad26.COVS vaccine OR EpiVacCorona vaccine) AND (Toxicity OR Vaccine Immunogenicity OR side effects OR adverse events) AND (randomized controlled trial OR double blind method OR clinical trial) (Table 1). A list of vaccines available at WHO was also used.

**Table 1 Medline search strategy**

Search items

1	COVID-19
2	SARS-CoV-2
3	2019-nCoV
4	Coronavirus
5	Or/1-4
6	vaccines
7	vaccination
8	COVID-19 vaccine
9	SARS-CoV-2 vaccine
10	BNT162 vaccine
11	mRNA-1273 vaccine
12	COVID-19 aAPC vaccine
13	INO-4800 vaccine
14	LV-SMENP-DC COVID-19 vaccine
15	Ad5-nCoV vaccine
16	ChAdOx1 COVID-19 vaccine
17	MNA SARS-CoV-2 S1 subunit vaccines

1	
2	
3	18 PittCoVacc
4	
5	19 Inactivated novel coronavirus 2019-CoV vaccine Vero cells
6	
7	20 Inactivated Vaccines
8	
9	21 SARS-CoV-2 inactivated vaccines
10	
11	22 Viral Vaccines
12	
13	23 Gam-COVID-Vac vaccine
14	
15	24 Ad26.COVS.S vaccine
16	
17	25 EpiVacCorona vaccine
18	
19	26 Or/6-25
20	
21	27 Toxicity
22	
23	28 Vaccine Immunogenicity
24	
25	29 side effects
26	
27	30 adverse events
28	
29	31 Or/27-30
30	
31	32 randomized controlled trial
32	
33	33 double-blind method
34	
35	34 clinical trial
36	
37	35 Or/32-34
38	
39	36 5 AND 26 AND 31 AND 35

### Study records

Four researchers (KSM, APFC, ACAS, and CLF) performed the selection of the studies of interest. Titles and abstracts will be read independently, and duplicate studies will be excluded. The same authors analyzed the selected texts to assess compliance with the inclusion criteria. A fifth reviewer, AKG, solves the discrepancies. The flowchart of this study is shown in Figure 1.

### [Insert Figure 1]

**Figure 1** Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

### Data collection process and management

A standardized data extraction form was developed and tested. Data from each included study will be extracted independently by two reviewers (ACAS and APFC), and any subsequent discrepancies will be resolved through discussion with a third reviewer (AKG). The data extracted will include information on authors, the year of publication, study location, type of study, main objectives, population, type of vaccine, follow-up of participants, rates of systemic events, gastrointestinal (GI) symptoms, injection site-related adverse effects, and serious vaccine-related adverse events (Table 2). Furthermore, participant characteristics (e.g., mean age, gender), and results for immunogenicity will be collected.

**Table 2** Adverse events of COVID-19 vaccines

Adverse Events

Systemic events reactions (10, 11)	Fever or hyperthermia or feverish, headaches, fatigue, vomiting, diarrhea, muscle pain, joint pain, cough, nausea, dyspnea, appetite impaired, dizziness, mucosal abnormality, pruritus [10, 11], hypersensitivity, syncope [10], asthenia, rhinorrhea, malaise, sore throat (throat irritation), pain in the oropharynx (pharyngalgia), hives, nasal congestion [12, 13].
Injection site adverse reactions (10-12)	Pain, induration, redness or erythema, swelling, itch, and muscular weakness [10-12].
Serious vaccine-related adverse event	Deaths, hospitalisation [13], Thrombotic complications [14, 15].

The study authors will be contacted in case of missing data and/or to resolve any uncertainties. In addition, any additional information will be recorded. All data entries will be checked twice. If we find a set of articles with similar characteristics based on the information in the data extraction table, we will

1  
2  
3 perform a meta-analysis using a random-effects model. If there is data that is not  
4 clear in some articles, the corresponding author will be contacted for possible  
5 clarification.  
6  
7  
8  
9

### 10 **Risk of bias in individual studies**

11 Three authors, KSM, ACAS, and APFC, will independently assess the risk  
12 of bias in the eligible studies using the Cochrane risk-of-bias tool [16]. The Risk  
13 of Bias 2 (RoB 2) tool [17] will be used to assess the risk of bias. Bias is assessed  
14 as a judgment (high, low, or unclear) for individual elements from five domains  
15 (selection, performance, attrition, reporting, and others).  
16  
17  
18  
19  
20  
21

### 22 **Data synthesis and analysis**

23 Data will be entered into the Review Manager software (RevMan5.2.3).  
24 This software allows the user to enter protocols; complete reviews; include text,  
25 characteristics of the studies, comparison tables, and study data; and perform  
26 meta-analyses. For dichotomous outcomes, we extracted or calculated the OR  
27 and 95% CI for each study. In case of heterogeneity ( $I^2 \geq 50\%$ ), the random-effects  
28 model will be used to combine the studies to calculate the OR and 95% CI, using  
29 the DerSimonian–Laird algorithm.  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Meta-bias**

39 To grade the strength of evidence from the included data, we will use the  
40 Grading of Recommendation Assessment, Development, and Evaluation  
41 (GRADE) [18] approach. The summary of the assessment will be incorporated  
42 into broader measurements to ensure the judgment of the risk of bias,  
43 consistency, directness, and precision. The quality of the evidence will be  
44 assessed based on the risk of bias, indirectness, inconsistency, imprecision, and  
45 publication bias.  
46  
47  
48  
49  
50  
51  
52

## 53 **DISCUSSION**

54 The COVID-19 pandemic represents one of the most significant global  
55 public health crises of this generation. Lockdown, quarantine, contact tracing, and  
56 case isolation are suggested as effective interventions to control the epidemic;  
57 however, they may present different results in different contexts because of the  
58  
59  
60



1  
2  
3 specific features of the COVID-19. The lack of implementation of continued  
4 interventions or effective treatments further contributes to discovering and using  
5 effective and safe vaccines [19,20].  
6  
7

8 For all these reasons, scientists worldwide entered a race to find a vaccine  
9 candidate useful in fighting the new coronavirus pandemic. Nevertheless, it is  
10 essential to note that a vaccine's production is not easy and quick. Before being  
11 released to the population, a vaccine must go through three phases of clinical  
12 trials that prove its safety and effectiveness. More volunteers are recruited at  
13 each stage, and the researchers analyze the test results to ensure that a vaccine  
14 can be licensed [21-23].  
15  
16  
17  
18  
19

20 One hundred seventy-three vaccines were in preclinical development and  
21 64 in clinical trials until January 20th, 2021. On December 31, 2020, the World  
22 Health Organization (WHO) listed the mRNA vaccine against COVID-19 for  
23 emergency use, making this Pfizer/BioNTech immunizer the first to receive WHO  
24 emergency validation from the beginning outbreak. Already, in January 2021  
25 emergency approval was granted to nine vaccines by regulatory authorities in  
26 different parts of the world [19, 24].  
27  
28  
29  
30  
31

32 With the starting vaccination, several studies were carried out to ascertain  
33 the safety of these vaccines, since they were produced in record time [25-27].  
34 Currently, one systematic review about the thematic showed that of eleven  
35 published clinical trials of COVID-19 vaccines included in study, adverse  
36 reactions reported were considered mild to moderate with few severe reactions  
37 which were unrelated to the test vaccine. Common adverse events were pain at  
38 the site of injection, fever, myalgia, fatigue, and headache. Serious adverse  
39 events were reported in four trials: COVID-19 Vaccine AstraZeneca (AZD1222)—  
40 168 SAE with only three related to the vaccine; Ad26.COV2.S- fou with none  
41 related to the testing vaccine; five with Comirnaty (BNT162b1) and one with  
42 Covaxin (BBV152) vaccine [24].  
43  
44  
45  
46  
47  
48  
49  
50

51 One limitation about the COVID-19 vaccine safety tested until now is that  
52 clinical trials of the safety and effectiveness have had low inclusion of vulnerable  
53 groups, for example, older persons, the first population to receive the whole  
54 vaccine. That's why pharmacovigilance post-marketing is necessary to  
55 surveillance new drugs, as a critical aspect of evaluating medicine safety and  
56 effectiveness, particularly in risk groups.  
57  
58  
59  
60

1  
2  
3 Other prevention approaches are likely to emerge in the coming months,  
4 including anti-viral agents, drugs may be to decrease disease progression,  
5 monoclonal antibodies, hyper-immune globulin, and convalescent titer If proven  
6 effective, these approaches could be used in high-risk individuals, including  
7 health care workers, other essential workers, and older adults [28 - 31]. It is  
8 essential to maintain protective measures such as washing hands frequently with  
9 soap and water or gel alcohol and covering the mouth with a forearm when  
10 coughing or sneezing.  
11

12  
13 For all the reasons mentioned above, this review is necessary and  
14 essential. The latter is a well-defined protocol registered with Prospero, well  
15 planned to include the largest possible number of vaccines, a significant number  
16 of vaccinated patients, thus providing safe and reliable results regarding the use  
17 of vaccines.  
18

## 19 20 21 22 23 24 25 26 27 28 **Ethics and Dissemination**

29  
30 This study will review published data, and thus it is unnecessary to obtain ethical  
31 approval. The findings of this systematic review will be published in a peer-  
32 reviewed journal.  
33  
34  
35

## 36 37 38 **Contributors**

39  
40 KSM, ACAS, and APFC contributed to the design of this review. KSM and ACAS  
41 drafted the protocol manuscript, and APFC and AKG revised it. KSM, AKG, and  
42 APFC developed the search strategies, and KSM, CLF, and ACAS will implement  
43 them. KSM, CLF, ACAS, and APFC will track potential studies, extract data, and  
44 assess quality. In cases of disagreement between the data extractors, AKG will  
45 advise on the methodology and will work as a referee. KSM will complete the data  
46 synthesis. All authors will approve the final version for publication.  
47  
48  
49  
50  
51

## 52 53 54 **Funding**

55  
56 The authors have not declared a specific grant for this research from any funding  
57 agency in the public, commercial, or not-for-profit sectors.  
58  
59  
60

## Competing interests

None declared.

## REFERENCES

- [1] Michael A Johansson, Talia M Quandelacy, Sarah Kada, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw Open*. 2021 Jan 4;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057.
- [2] SimranPreet Kaur, Vandana Gupta. COVID-19 Vaccine: A comprehensive status report. *Virus Res*. 2020;15;288:198114. doi: 10.1016/j.virusres.2020.198114.
- [3] Barney S Graham. Rapid COVID-19 vaccine development. *Science*. 2020;368(6494):945-946. doi: 10.1126/science.abb8923.
- [4] MangalakumariJeyanathan, Sam Afkhami, Fiona Smaill, Matthew S Miller, Brian D Lichty, Zhou Xing. Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol*. 2020;20(10):615-632. doi: 10.1038/s41577-020-00434-6.
- [5] Guido Forni, Alberto Mantovani. COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ*. 2021 Feb;28(2):626-639. doi: 10.1038/s41418-020-00720-9.
- [6] Pollard AJ. Notice of addendum to article reporting Oxford trial of ChAdOx1nCoV-19 vaccine. *Lancet*. 2020;396:e89. doi: 10.1016/S0140-6736(20)32467-3.
- [7] Miao Cao, Xiaojie Su, ShiboJiang. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks. *Stem Cell Reports*. 2021 Mar 9; 16(3): 398–411. doi: 10.1016/j.stemcr.2020.12.010
- [8] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- [9] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009;339:b2700.

1  
2  
3 [10] Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang  
4 Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ,  
5 Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a  
6 recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,  
7 open-label, non-randomised, first-in-human trial. *Lancet*. 2020 Jun  
8 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3. Epub 2020  
9 May 22. PMID: 32450106; PMCID: PMC7255193.

10 [11] Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang  
11 L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y,  
12 Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW,  
13 Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus  
14 type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a  
15 randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020 Aug  
16 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul  
17 20. PMID: 32702299.

18 [12] Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV,  
19 Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG,  
20 Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA,  
21 Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV,  
22 Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA,  
23 Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV,  
24 Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5  
25 vector-based heterologous prime-boost COVID-19 vaccine in two formulations:  
26 two open, non-randomised phase 1/2 studies from Russia. *Lancet*. 2020 Sep  
27 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep  
28 4. Erratum in: *Lancet*. 2021 Jan 9;397(10269):98. PMID: 32896291; PMCID:  
29 PMC7471804.

30 [13] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S,  
31 Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman  
32 AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock  
33 KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C,  
34 Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine  
35 Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine  
36 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind,  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 randomised controlled trial. *Lancet*. 2020 Aug 15;396(10249):467-478. doi:  
4 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Erratum in: *Lancet*. 2020  
5 Aug 15;396(10249):466. Erratum in: *Lancet*. 2020 Dec 12;396(10266):1884.  
6  
7 PMID: 32702298; PMCID: PMC7445431.

8  
9  
10 [14] M. Porres-Aguilar, M.C. Guerrero-de León, F.A. Grimaldo-Gómez, R  
11 Izaguirre-Ávila, A Cabrera-Rayó, L.E. Santos-Martínez, et al. Thrombotic  
12 complications in severe COVID-19: focus on venous thromboembolism,  
13 thromboprophylaxis and anticoagulation. *CirCir*, 89 (2021), pp. 115-119.  
14 <http://dx.doi.org/10.24875/CIRU.20000879>

15  
16 [15] Mateo Porres-Aguilar, Alejandro Lazo-Langner, Arturo Panduro, Misael  
17 Uribe. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An  
18 emerging cause of splanchnic vein thrombosis. *Ann Hepatol*. Jul-Aug  
19 2021;23:100356. doi: 10.1016/j.aohep.2021.100356.

20  
21 [14] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane collaboration's  
22 tool for assessing risk of bias in randomised trials. *Cochrane bias methods group*;  
23 *Cochrane statistical methods group*. *BMJ* 2011;343.

24  
25 [15] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates  
26 CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell  
27 S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T,  
28 McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR,  
29 Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in  
30 randomised trials. *BMJ*. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898. PMID:  
31 31462531.

32  
33 [16] Balshem H, Helfand M, Schünemann HJ, et al. Grade guidelines: 3. rating  
34 the quality of evidence. *J ClinEpidemiol* 2011;64:401–6.  
35 10.1016/j.jclinepi.2010.07.015

36  
37 [17] Iezadi S, Azami-Aghdash S, Ghiasi A, Rezapour A, Poursaghari H,  
38 Pashazadeh F, et al. Effectiveness of the non-pharmaceutical public health  
39 interventions against COVID-19; a protocol of a systematic review and realist  
40 review. *Plos One*. 2020; 15(9): e0239554. doi:10.1371/journal.pone.0239554

41  
42 [18] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.  
43 Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus  
44 Disease 2019 (COVID-19). *JAMA*. 2020. doi:10.1001/jama.2020.12839


- 1  
2  
3 [19] WHO. Coronavirus disease (COVID-19) situation report—181. Geneva:  
4 World Health Organization, 2020.  
5  
6 [20] Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al. Current Status  
7 of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus  
8 Disease 2019 (COVID-19). *J. Microbiol. Biotechnol.* 2020;30(3):313-324  
9  
10 [21] Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-  
11 19, an emerging coronavirus infection: advances and prospects in designing and  
12 developing vaccines, immunotherapeutics, and therapeutics. *Human Vaccines*  
13 & Immunotherapeutics. 2020;1–7. doi:10.1080/21645515.2020.1735227  
14  
15 [22] Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S,  
16 et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against  
17 SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised  
18 controlled trial. *Lancet.* 2020;396(10249): 467-478.  
19  
20 [23] Ong E, Wong M, Huffman A and He Y. COVID-19 coronavirus vaccine design  
21 using reverse vaccinology and machine learning. *Front. Immunol.* 2020. 11:1581.  
22 doi:10.3389/fimmu.2020.01581  
23  
24 [24] Kaur RJ, Dutta S, Bhardwaj P, Charan J, Sameer Dhingra S, Mitra P, et al.  
25 Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.  
26 *Ind J ClinBiochem.* 2021. [https://link.springer.com/article/10.1007/s12291-021-](https://link.springer.com/article/10.1007/s12291-021-00968-z)  
27 [00968-z](https://link.springer.com/article/10.1007/s12291-021-00968-z))  
28  
29 [25] Chen J, Cai Y, Chen Y, P. Williams A, Gao Y, Zeng J. Nervous and Muscular  
30 Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-  
31 Analysis of Clinical Trials. *Vaccines.* 2021; 9:939.  
32 <https://doi.org/10.3390/vaccines9080939>.  
33  
34 [26] Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al.  
35 Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on  
36 covid-19 related symptoms, hospital admissions, and mortality in older adults in  
37 England: test negative case-control study. *BMJ.* 2021;373:n1088. doi:  
38 10.1136/bmj.n1088  
39  
40 [27] Iheanacho CO, Eze UIH, Adida EA. A systematic review of effectiveness of  
41 BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the  
42 general population. *Bull Natl Res Cent.* 2021;45:150.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 [28] Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic  
4 Treatments for Coronavirus Disease 2019 (COVID-19). JAMA. 2020.  
5 doi:10.1001/jama.2020.6019.  
6  
7

8 [29] Yuan P, Ai P, Liu Y, Ai Z, Wang Y, Cao W, Xia X, Zheng JC. Safety,  
9 Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review  
10 and Meta-Analysis. medRxiv [Preprint]. 2020 Nov 4:2020.11.03.20224998. doi:  
11 10.1101/2020.11.03.20224998. PMID: 33173896; PMCID: PMC7654888.  
12  
13  
14

15 [30] Dhakal N, Poudyal A, Gyanwali P. Pharmacological Treatment for the  
16 Management of COVID 19: A Narrative Review. JNMA J Nepal Med Assoc. 2021  
17 Jul 1;59(238):614-621. doi: 10.31729/jnma.5920. PMID: 34508415.  
18  
19  
20

21 [31] Bestetti RB, Furlan-Daniel R, Silva VMR. Pharmacological Treatment of  
22 Patients with Mild to Moderate COVID-19: A Comprehensive Review. Int J  
23 Environ Res Public Health. 2021 Jul 5;18(13):7212. doi:  
24 10.3390/ijerph18137212. PMID: 34281149; PMCID: PMC8297311.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1** Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

Figure 1 Flow diagram of the search for eligible studies on the side effects, safety, and toxicity of the COVID-19 vaccine: CENTRAL, Cochrane Central Register of Controlled Trials.

168x222mm (300 x 300 DPI)



**PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\***

Section and topic	Item No	Checklist item	
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	01
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	-
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	02
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	01
	3b	Describe contributions of protocol authors and identify the guarantor of the review	01
Contributions			
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	-
Support:			
Sources	5a	Indicate sources of financial or other support for the review	x
Sponsor	5b	Provide name for the review funder and/or sponsor	x
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	-
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	03
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	04
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	05
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	05

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	06
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	08
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	08
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	09
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	09
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	09
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	09
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	10
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	10
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	10
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	10
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	10

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*